TY - JOUR
T1 - French women's breast self-examination practices with time after undergoing BRCA1/2 genetic testing
AU - Maheu, C.
AU - Apostolidis, T.
AU - Petri-Cal, A.
AU - Mouret-Fourme, E.
AU - Gauthier-Villars, M.
AU - Lasset, C.
AU - Berthet, P.
AU - Fricker, J. P.
AU - Caron, O.
AU - Luporsi, E.
AU - Gladieff, L.
AU - Nogues, C.
AU - Julian-Reynier, C.
N1 - Funding Information:
Longy, Tan Dat NGuyen, Claude Picard, Irwin Piot, Hagay Sobol, Dominique Stoppa-Lyonnet, Laurence Venat-bouvet, Philippe Ven-nin, Hélène Zattara-Cannoni. The study was financially supported by Institut National du Cancer INCA R08097AA/RPT08011AAA.
PY - 2012/1/1
Y1 - 2012/1/1
N2 - To assess the impact of BRCA1/2 genetic test results on cancer-free women's breast-self-examination (BSE) practices and to prospectively determine their influence on psychological functioning. A prospective longitudinal study on French women's BSE practices and frequencies in BRCA1/2 carriers (N = 217) and non-carriers (N = 313) 1 and 2 years following disclosure of the test results, along with psychological factors predicting BSE practices. Before disclosure, BSE was practised by 47.2% of the women, and increased to 57.3% 1 year later. No change in the women's practices was noted between 12 and 24 months after the test. Carriers and non-carriers practicing regularly BSE at baseline were, respectively 8 to 6 times more likely to be practising BSE regularly at 12 months after being tested. Among the carriers, having fewer depressive symptoms at baseline and believing in the ability of BSE to detect breast cancer were found to be the most decisive factors associated with BSE practices 1 year after disclosure, following adjustment for BSE baseline practices. Among the non-carriers, believing in the ability of BSE to detect breast cancer, greater post-Test anxiety, and a higher perceived risk of breast cancer were found to be predictors of post-Test BSE practices after adjusting for BSE baseline practices. In France, where performing BSE is neither mandatory nor recommended, an increase in BSE practices was found to occur after disclosure of women's genetic test results, regardless of their carrier status.
AB - To assess the impact of BRCA1/2 genetic test results on cancer-free women's breast-self-examination (BSE) practices and to prospectively determine their influence on psychological functioning. A prospective longitudinal study on French women's BSE practices and frequencies in BRCA1/2 carriers (N = 217) and non-carriers (N = 313) 1 and 2 years following disclosure of the test results, along with psychological factors predicting BSE practices. Before disclosure, BSE was practised by 47.2% of the women, and increased to 57.3% 1 year later. No change in the women's practices was noted between 12 and 24 months after the test. Carriers and non-carriers practicing regularly BSE at baseline were, respectively 8 to 6 times more likely to be practising BSE regularly at 12 months after being tested. Among the carriers, having fewer depressive symptoms at baseline and believing in the ability of BSE to detect breast cancer were found to be the most decisive factors associated with BSE practices 1 year after disclosure, following adjustment for BSE baseline practices. Among the non-carriers, believing in the ability of BSE to detect breast cancer, greater post-Test anxiety, and a higher perceived risk of breast cancer were found to be predictors of post-Test BSE practices after adjusting for BSE baseline practices. In France, where performing BSE is neither mandatory nor recommended, an increase in BSE practices was found to occur after disclosure of women's genetic test results, regardless of their carrier status.
KW - BRCA1/2 families
KW - Breast self-examination practices
KW - France
KW - Psychological factors
UR - http://www.scopus.com/inward/record.url?scp=84864723719&partnerID=8YFLogxK
U2 - 10.1007/s10689-012-9512-z
DO - 10.1007/s10689-012-9512-z
M3 - Article
C2 - 22350503
AN - SCOPUS:84864723719
SN - 1389-9600
VL - 11
SP - 269
EP - 278
JO - Familial Cancer
JF - Familial Cancer
IS - 2
ER -